Articles Guselkumab versus secukinumab for the treatment of moderatetosevere psoriasis ECLIPSE results from a phase 3 randomised controlled trial

[Articles] Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

19:57 EDT 8 Aug 2019 | The Lancet

Guselkumab showed superior long-term efficacy based on PASI 90 at week 48 when compared with secukinumab for treating moderate-to-severe psoriasis. This finding could assist health-care providers in their decision making process when selecting a biologic for treating moderate-to-severe psoriasis.

More From BioPortfolio on "[Articles] Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial"